FUSN(Delisted)
Fusion·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 0
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FUSN
Fusion Pharmaceuticals Inc.
A clinical-stage oncology company that developing next-generation radiopharmaceuticals as precision medicines
270 Longwood Rd., S., Hamilton, Ontario, Canada L8P 0A6
--
Fusion Pharmaceuticals Inc. was incorporated in December 2014 under the laws of the Ontario Business Corporation Act. The company is a clinical-stage oncology company dedicated to the development of next-generation radiopharmaceuticals as precision medicines. The company has developed the Targeted Alpha Therapy (TAT) platform, as well as proprietary Fast-Clear connector technology, capable of connecting alpha-particle-emitting isotopes with antibodies and other targeted molecules to selectively deliver alpha-particle payloads to tumors. The company's TAT platform is based on research and insight into the basic biology of α-emitting radiopharmaceuticals and differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, and imaging diagnostic development.
Company Financials
EPS
FUSN has released its 2024 Q1 earnings. EPS was reported at -0.4, versus the expected -0.37, missing expectations. The chart below visualizes how FUSN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
